Abstract Library

#3176 Tissue sample collection from patients with neuroendocrine tumor (NET) treated with peptide receptor radionuclide therapy (PRRT) for future blood disease research

Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective treatment for patients with metastatic NET. However, the development of therapy-related myeloid neoplasms (t-MN) is an infrequent but serious complication. T-MN after PRRT occurs at higher frequency compared to other solid tumor chemotherapies and harbour unfavourable genetic mutations with poor treatment outcomes. Prospective data is needed to explore pre-existing genetic factors and predictive biomarkers to minimise t-MN risk.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kong G

Authors: Kong G, Michael M, Alipour R, Akhurst T, Hicks R,

Keywords: t-MN, PRRT, PRCRT, marrow biopsy,

#3161 Phase 1 trial of PARP inhibitor combined with 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastatic neuroendocrine tumor - PARLuNET

Introduction: 177Lu-DOTA-Octreotate (177Lu-DOTATATE) is an effective treatment for patients with grade 1 and 2 NET. However, strategies are required to optimize treatment efficacy and outcomes. Combining a DNA-repair modifying agent could further enhance radiation efficacy. Pre-clinical data supports that a PARP inhibitor (PARPi) combined with PRRT significantly enhances NET cell death and animal survival compared to 177Lu-DOTATATE alone. This combination strategy aims to enhance radiation efficacy from PRRT.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kong G

Authors: Kong G, Hatzimihalis A, Hogg A, Bressel M, Hicks R,

Keywords: PRRT, PARP inhibitor, combination therapy, NET, pancreatic, phase 1,

#2937 Brain Metastasis in Patients with Neuroendocrine Neoplasia of Gastroenteropancreatic Origin: A Single Centre Experience

Introduction: Brain metastasis (BrMet) in patients (pts) with neuroendocrine neoplasia (NEN) of gastroenteropancreatic (GEP) origin is extremely rare. Data on management and outcome are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Saghebi J, Hicks R, Michael M, Kong G,

Keywords: neuroendocrine neoplasia, brain metastasis, gastroenteropancreatic, PRRT,

#2842 Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) – Molecular Imaging, Pathologic Features and Patient Outcomes

Introduction: Transformation of lower grade to Grade 3 (G3) NEN potentially impacts prognosis & treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kong G, Callahan J, Prall O, Michael M, Hicks R,

Keywords: Transformation, G3 NEN, PET imaging, mutation, PRRT, prognosis,

#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma

Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kamel Hasan O

Authors: Kamel Hasan O, Ravi Kumar A, Kong G, Grozinsky-Glasberg S, Hicks R,

Keywords: esthesioneuroblastoma, peptide receptor radionuclide therapy, lutetium-177 dotatate,